Association of TNF-alpha –308 G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis: a meta-analysis

[1]  A. Bakkaloğlu,et al.  Recurrent auricular chondritis and cartilage repair , 2005, Annals of the rheumatic diseases.

[2]  S. Bae,et al.  The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. , 2005, Rheumatology.

[3]  F. Nagy,et al.  Investigation of the Prognostic Value of TNF-α Gene Polymorphism among Patients Treated with Infliximab, and the Effects of Infliximab Therapy on TNF-α Production and Apoptosis , 2004, Pathobiology.

[4]  A. Aguirre,et al.  Tumour necrosis factor‐α (TNF‐α) levels and influence of −308 TNF‐α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis , 2004 .

[5]  A. Radbruch,et al.  Differential antibody recognition of the 349–364aa B-cell epitope of human La/SSB protein and its phosphorylated analogue , 2004, The Journal of experimental medicine.

[6]  Nathalie Balandraud,et al.  Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[7]  L. Padyukov,et al.  Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[8]  Richard W. Martin,et al.  Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. , 2002, Arthritis and rheumatism.

[9]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[10]  R. Allen.  Polymorphism of the human TNF-α promoter — random variation or functional diversity? , 1999 .

[11]  J. Belaiche,et al.  Tumour necrosis factor (TNF) gene polymorphism influences TNF‐α production in lipopolysaccharide (LPS)‐stimulated whole blood cell culture in healthy humans , 1998, Clinical and experimental immunology.

[12]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[13]  George Davey Smith,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[14]  F. Breedveld,et al.  Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? , 1997, British journal of rheumatology.

[15]  M. Rn,et al.  The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.

[16]  A. Peña,et al.  Secretion of Tumour Necrosis Factor α and Lymphotoxin α in Relation to Polymorphisms in the TNF Genes and HLA‐DR Alleles. Relevance for Inflammatory Bowel Disease , 1996 .

[17]  M. Feldmann,et al.  TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.

[18]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[19]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[20]  J. Cavaleiro,et al.  Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. , 2005, Annals of the rheumatic diseases.

[21]  F. Nagy,et al.  Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. , 2004, Pathobiology : journal of immunopathology, molecular and cellular biology.

[22]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[23]  R. Allen.  Polymorphism of the human TNF-alpha promoter--random variation or functional diversity? , 1999, Molecular immunology.

[24]  G. Davey Smith,et al.  Meta-analyses of randomised controlled trials. , 1997, Lancet.

[25]  A. Peña,et al.  Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. , 1996, Scandinavian journal of immunology.

[26]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.